Thomas Hartung

Thomas Hartung, MD Ph.D., is AxoSim’s Consulting VP of Scientific Affairs and the inventor of the Mini-Brain platform. Thomas believed in AxoSim’s vision to change the paradigm for neurological drug development and chose AxoSim to commercialize his groundbreaking technology. He is also the Doerenkamp-Zbinden-Chair for Evidence-based Toxicology at Johns Hopkins Bloomberg School of Public Health and the Whiting School of Engineering, Baltimore, in Environmental Health and Engineering. He is also the Director of Centers for Alternatives to Animal Testing (CAAT, HTTP://CAAT.JHSPH.EDU) of both Hopkins and the University of Konstanz, Germany. CAAT hosts the secretariat of the Evidence-based Toxicology Collaboration, the Good Read-Across Practice Collaboration, the Good Cell Culture Practice Collaboration, the Green Toxicology Collaboration, and the Industry Refinement Working Group. He is the former Head of the European Commission’s Center for the Validation of Alternative Methods (ECVAM), Ispra, Italy, and has authored more than 550 scientific publications.